Clovis Oncology, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2023-07-11: Form 8-K; Period of report 2023-07-10; Description 1.03 Bankruptcy or Receivership; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events; Details 1.03.
- 2023-06-30: Form 8-K; Period of report 2023-06-30; Description 3.03 Material Modification to Rights of Security Holders; 7.01 Regulation FD Disclosure; Details 3.03.
- 2023-06-02: Form 8-K; Period of report 2023-05-26; Description 7.01 Regulation FD Disclosure; 8.01 Other Events; Details 7.01.
- 2023-05-03: Form 8-K; Period of report 2023-05-02; Description 7.01 Regulation FD Disclosure; Details 7.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2023-07-11 | 8-K | 2023-07-10 | 1.03 Bankruptcy or Receivership; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 1.03 As previously disclosed, on December 11, 2022, Clovis Oncology, Inc. (the “Company”) and certain of its subsidiaries, Clovis Oncology Ireland Limited and Clovis Oncology UK Limited (together with the Company, the “Debtors”), filed voluntary petitions under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (such court, the “Court” and such cases, the “Cases”). 3.03 The disclosure under Item 1.03 of this Current Report is incorporated herein by reference. 5.01 The disclosure under Item 1.03 of this Current Report is incorporated herein by reference. 5.02 In connection with the effectiveness of the Plan, the directors and officers of the Company have been discharged from their duties and terminated from such positions. 8.01 In conjunction with the effectiveness of the Plan and the cancellation of all of its outstanding shares of common stock, the Company intends to file post-effective amendments to each of its Registration Statements on Form S-3 and Form S-8 and promptly file a Form 15 with the Securities and Exchange Commission to deregister its securities under Section 12(g) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and suspend its reporting obligations under the Exchange Act. | d514612d8k.htm |
| 2023-06-30 | 8-K | 2023-06-30 | 3.03 Material Modification to Rights of Security Holders; 7.01 Regulation FD Disclosure | 3.03 As previously disclosed, on December 11, 2022, Clovis Oncology, Inc. (the “Company”) and certain of its subsidiaries (such subsidiaries being Clovis Oncology Ireland Limited (“Clovis Ireland”) and Clovis Oncology UK Limited (“Clovis UK”, and together with the Company and Clovis Ireland, the “Debtors”)) filed voluntary petitions under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (such court, the “Court” and such cases, the “Cases”). 7.01 On June 30, 2023, the Company, Clovis UK and Clovis Ireland each filed their monthly operating reports (collectively, the “Monthly Operating Reports”), with the Court for the reporting month ended May 31, 2023, copies of which are attached hereto as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, respectively, and are incorporated herein by reference. | d423552d8k.htm |
| 2023-06-02 | 8-K | 2023-05-26 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On June 1, 2023, the Company, Clovis UK and Clovis Ireland each filed their monthly operating reports (collectively, the “Monthly Operating Reports”), with the Court for the reporting month ended April 30, 2023, copies of which are attached hereto as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, respectively, and are incorporated herein by reference. 8.01 On May 26, 2023, the Company received a complete response letter from the United States Food and Drug Administration (the “FDA”) in which the FDA stated that it would not approve the Company’s supplemental new drug application (the “sNDA”) seeking approval of Rubraca in the United States for the maintenance treatment of women with advanced ovarian cancer who are in complete or partial response to first-line platinum-based chemotherapy (first-line maintenance). | d473874d8k.htm |
| 2023-05-03 | 8-K | 2023-05-02 | 7.01 Regulation FD Disclosure | 7.01 On May 2, 2023, the Company, Clovis UK and Clovis Ireland each filed their monthly operating reports (collectively, the “Monthly Operating Reports”), with the Court for the reporting month ended March 31, 2023, copies of which are attached hereto as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, respectively, and are incorporated herein by reference. | d262776d8k.htm |
| 2023-05-01 | 8-K | 2023-05-01 | 2.01 Completion of Acquisition or Disposition of Assets | 2.01 As previously disclosed, on December 11, 2022, Clovis Oncology, Inc. (the “Company”) and certain of its subsidiaries, Clovis Oncology Ireland Limited and Clovis Oncology UK Limited (together with the Company, the “Debtors”) filed voluntary petitions under Chapter 11 of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (such court, the “Court” and such cases, the “Cases”). | d489588d8k.htm |
| 2023-04-14 | 8-K | 2023-04-14 | 2.01 Completion of Acquisition or Disposition of Assets | 2.01 As previously disclosed, on December 11, 2022, Clovis Oncology, Inc. (the “Company”) and certain of its subsidiaries, Clovis Oncology Ireland Limited and Clovis Oncology UK Limited (together with the Company, the “Debtors”) filed voluntary petitions under Chapter 11 of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (such court, the “Court” and such cases, the “Cases”). | d458873d8k.htm |
| 2023-04-06 | 8-K | 2023-04-05 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d492602d8k.htm |
| 2023-03-31 | 8-K | 2023-03-30 | 7.01 Regulation FD Disclosure | 7.01 On March 30, 2023, the Company, Clovis UK and Clovis Ireland each filed their monthly operating reports (collectively, the “Monthly Operating Reports”), with the Court for the reporting month ended February 28, 2023, copies of which are attached hereto as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, respectively, and are incorporated herein by reference. | d495137d8k.htm |
| 2023-03-02 | 8-K | 2023-03-01 | 7.01 Regulation FD Disclosure | 7.01 On March 1, 2023, the Company, Clovis UK and Clovis Ireland each filed their monthly operating reports (collectively, the “Monthly Operating Reports”), with the Court for the reporting month ended January 31, 2023, copies of which are attached hereto as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, respectively, and are incorporated herein by reference. | d467329d8k.htm |
| 2023-02-16 | 8-K | 2023-02-09 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 As previously disclosed, on December 11, 2022, Clovis Oncology, Inc. (the “Company”) and its subsidiaries, Clovis Oncology UK Limited and Clovis Oncology Ireland Limited (together with the Company, the “Debtors”) filed voluntary petitions under Chapter 11 of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”). | d455266d8k.htm |
| 2023-02-13 | 8-K | 2023-02-09 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On February 9, 2023, the Company, Clovis UK and Clovis Ireland each filed their monthly operating reports (collectively, the “Monthly Operating Reports”), with the Court for the reporting month ended December 31, 2022, copies of which are attached hereto as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, respectively, and are incorporated herein by reference. 8.01 In connection with the Cases, the Debtors have obtained customary relief from the Court to transition into Chapter 11 without material disruption to their operations, including paying employee wages and benefits, maintaining relationships with vendors and suppliers in order to continue to supply Rubraca to patients, continuing its cash management system in the ordinary course of business, manage ongoing clinical trials and maintain regulatory approvals. | d400299d8k.htm |
| 2023-01-12 | 8-K | 2023-01-06 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth above in Item 1.01 of this Current Report on Form 8-K regarding the DIP Financing Agreement and the Security Agreement is incorporated by reference herein. | d382753d8k.htm |